Seralutinib Improves Pulmonary Arterial Blood Vessel Volume Distribution in Pulmonary Arterial Hypertension (PAH): Results of the TORREY Phase 2 Imaging Substudy

Seralutinib Improves Pulmonary Arterial Blood Vessel Volume Distribution in Pulmonary Arterial Hypertension (PAH): Results of the TORREY Phase 2 Imaging Substudy

PHPN – Sept 2023

Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).

PROSERA clinical trial: NCT05934526

Learn more about the study